Standigm Raises US $11.5 Million in Series B Round Funding to advance its AI-powered drug pipelines toward license-out

Updated:

Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, announced it has raised 11.5 million dolloar in a Series B funding round led by Mirae Asset Venture Investment and Mirae Asset Capital. Standigm will use the funds to scale the AI technology platforms and advance its drug discovery pipelines toward license-out. The new round brings Standigm’s total financing to $15 million.

Read more in English press

DealStreetAsia, Bio-itworld, TechStartups

Read more in Korean press

SeoulDaily, MK

Tags: AI-driven drug discovery , drug pipelines , Investment , Standigm

Categories: News